Category Swissmedic

Swissmedic updates to guidances on time limits for authorisation applications, formal requirements and product information

In this post, information is provided on the following updated guidance documents: Changes to the guidance document Time limits for authorisation applications Swissmedic is shortening the procedural time limits for applications for new authorisation of medicinal products with known active…

Read MoreSwissmedic updates to guidances on time limits for authorisation applications, formal requirements and product information

Revised Interpretation of the Mutual Recognition Agreement (MRA) between Switzerland and Canada

31 January 2025 The Canada-Switzerland MRA on Medicinal Products: Drug GMP Compliance Certification, Sectoral Annex on GMP has been in force since 2000. The text of the MRA has not yet been revised as this interpretation was possible on the…

Read MoreRevised Interpretation of the Mutual Recognition Agreement (MRA) between Switzerland and Canada

Swissmedic- Changes to the guidance documents Fast-track authorisation procedure and Temporary authorisation for human medicinal products

The processes for the following have been optimised: Normally, if the criteria for an FTP or a temp.auth. / temp.AI cannot be conclusively evaluated following the assessment of the submitted documents by Swissmedic, an Accelerated Application HeAring (AAA) usually takes…

Read MoreSwissmedic- Changes to the guidance documents Fast-track authorisation procedure and Temporary authorisation for human medicinal products